&bgr;-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D &bgr;-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.